Early Prediction of Acute Kidney Injury Among Patients Admitted to Surgical ICU
NCT ID: NCT04554628
Last Updated: 2021-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
200 participants
INTERVENTIONAL
2019-09-14
2020-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The current study tries to evaluate the value of urinary markers as early predictors of possible development of AKI in patients admitted to surgical ICU.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Prediction of Acute Kidney Injury in High Risk Patients After Non-cardiac Surgery
NCT03880110
The Predictive Value of Doppler Based Renal Ultrasound and Urinary Oxygen Tension for Prediction of Acute Kidney Injury After Open Heart Surgery
NCT07037485
Role of Some Biochemical Indices for Prediction of Acute Kidney Injury in Intensive Care Unit Patients in Upper Egypt
NCT06791200
Preventing Acute Kidney Injury and Improving Outcome in Critically Ill Patients Utilising Risk Prediction Score
NCT03178435
Machine Learning Models for Prediction of Acute Kidney Injury After Noncardiac Surgery
NCT06146829
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Diagnosis of AKI Development of AKI within the first 48 hours after ICU admission and its staging will be defined according to the Acute Kidney Injury Network criteria. Each stage will be defined by the extent of change in serum creatinine level (∆SCr) as follows: Mild if Scr was increased by ≥0.3 mg/ml or ∆SCr was ≥1.5-2-fold from baseline, Moderate if ∆SCr was \>2-3-fold from baseline and Severe if ∆SCr was increase by \>3-fold from baseline .
Laboratory investigations Blood samples will be sent for estimation of serum creatinine (SCr) . Urine samples will be sent for spot creatinine , UNGAL, KIM1.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Urinary human neutrophil gelatinase-associated lipocalin
Urinary human neutrophil gelatinase-associated lipocalin (U-NGAL) measurement
ELISA test in urine
enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients
Urinary human kidney injury molecule 1 (U-KIM1)
Urinary human kidney injury molecule 1 (U-KIM1) measurement group
ELISA test in urine
enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ELISA test in urine
enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* Patients had renal surgery
* Patients maintained on renal replacement therapy
* Patients had diabetic nephropathy.
* Patients had liver disease, endocrinopathies.
* Patients morbid obesity that was defined as body mass index (BMI) \>35 kg/m2 .
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MOHAMMED FAWZI ALI ABOSAMAK
lecturer of anesthesia and intensive care
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohammed Abosamak
Role: PRINCIPAL_INVESTIGATOR
Security Forces Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Security Forces Hospital
Riyadh, , Saudi Arabia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Security forces hospital
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.